STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Ticker SymbolSTAA
Company nameSTAAR Surgical Co
IPO dateFeb 24, 1992
CEOMr. Stephen C. (Steve) Farrell, CPA
Number of employees1157
Security typeOrdinary Share
Fiscal year-endFeb 24
Address1911 Walker Ave
CityMONROVIA
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code91016
Phone16263037902
Websitehttps://www.staar.com/
Ticker SymbolSTAA
IPO dateFeb 24, 1992
CEOMr. Stephen C. (Steve) Farrell, CPA
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data